US-CONGRESS HR4993: Joe Fiandra Access to Home Infusion Act of 2025
HR4993, the Joe Fiandra Access to Home Infusion Act of 2025, has been ordered to be reported as amended. This bill aims to expand Medicare coverage for home infusion therapy, potentially increasing demand for infusion drugs and supplies. For pharmaceutical manufacturers, this may affect production planning, supply chain, and compliance with cGMP and DSCSA requirements.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities involved in infusion drugs should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline; monitor as bill advances through Congress.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The bill was ordered to be reported with amendments, signaling progress toward expanded Medicare coverage for home infusion therapy. This could increase demand for infusion-related pharmaceuticals and require adjustments in production and distribution.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities involved in infusion drugs
What you must do
Monitor the bill's progress and assess potential impact on production capacity, supply chain, and compliance with FDA regulations (cGMP, DSCSA) for infusion drugs.
Deadline
No immediate deadline; monitor as bill advances through Congress.
Source: https://www.congress.gov/bill/119th-congress/house-bill/4993
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Justice Department eases restrictions on some marijuana products - CBS News
- Experimental Drugs Without FDA Approval Are Now Legal in Montana - VICE
- Feds give 2-year approval to Florida’s Canadian prescription drug importation plan - Florida Politics
- GLP‑1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters - JD Supra
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight